Director
Sarcoma Oncology Research Center
Erlinda Maria de Guzman Gordon, MD, received her MD degree from the University of Santo Tomas College of Medicine & Surgery, completed pediatric residency at Mount Sinai Medical Center, Cleveland OH in 1976, and post-doctoral fellowship in Pediatric Hematology/Oncology from Case Western Reserve University, Rainbow Babies and Childrens Hospital, Cleveland OH. She served as Associate Professor of Pediatrics at Case Western Reserve University, was recruited to Childrens Hospital of Los Angeles in 1989, and served as Tenured Professor of Pediatrics at USC Keck School of Medicine. Dr. Gordon received Board Certification in Pediatric Hematology/Oncology in 1992.
Dr. Gordon is a practicing medical oncologist and serves as Director of Biological and Immunological Therapies and Chairman of the Institutional Biosafety Committee at the Cancer Center of Southern California, an academic medical institution that conducts over 25 active pharma-sponsored clinical trials for cancer. She is principal investigator of 3 innovative investigator-initiated cancer immunotherapy trials for sarcoma. She is an active member of the American Society of Clinical Oncology, Society of Immunotherapy for Cancer, American Association for Clinical Research, Connective Tissue Oncology Society, etc.
Dr. Gordon is also President of the Aveni Foundation, a 501c3 public charity, whose mission is to expedite the development of gene targeted technologies for cancer and COVID-19. Dr. Gordon is internationally known for the invention of DeltaRex-G, the first and, so far, only, tumor/disease-targeted genetic medicine that has evoked long term survival in patients with Stage 4 cancer, and gained Accelerated Approval for chemotherapy resistant solid malignancies in the Philippines in 2007, orphan drug designation for pancreatic cancer, soft tissue sarcoma and osteosarcoma in 2008, and Fast Track Designation for pancreatic cancer in the United States in 2009. Currently, Dr. Gordon serves as Sponsor/Principal Investigator of Blessed: An Expanded Access Program Using DeltaRex-G for Advanced Sarcoma and Pancreatic Cancer.